1-10 of 10
Christopher Parrish, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD PhD, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD
Journal: Blood
Blood (2015) 126 (23): 394.
https://doi.org/10.1182/blood.V126.23.394.394
Published: 2015
Journal Articles

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Sam H Ahmedzai, MBChB BSc FRCP, John A Snowden, MD FRCP, FRCPath, Angela Cox, BA MA PhD, David A Cairns, Cathy D Williams, Anna Hockaday, Jamie Cavenagh, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3180.
https://doi.org/10.1182/blood.V126.23.3180.3180
Published: 2015
Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, David A Cairns, Cathy Williams, A Hockaday, J. D. Cavenagh, MD MRCP, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1981.
https://doi.org/10.1182/blood.V126.23.1981.1981
Published: 2015
Journal Articles

Combination Therapy with Reovirus and Immunomodulatory Drugs Induces Direct Oncolytic and Immune-Mediated Killing of Multiple Myeloma Cells and Overcomes Stromal-Mediated Microenvironmental Protection

Christopher Parrish, MD, Gina B Scott, PhD, Matt Coffey, Alan Melcher, MD, Fiona Errington-Mais, PhD, Gordon Cook, MD
Journal: Blood
Blood (2014) 124 (21): 4778.
https://doi.org/10.1182/blood.V124.21.4778.4778
Published: 2014
Journal Articles

Th 17 Cells Are Increased in the Bone Marrow but Not the Peripheral Blood in Multiple Myeloma and Demonstrate Defective Functionality and Aberrant Phenotypes

Christopher Parrish, MD, Gina B Scott, PhD, Graham Cook, PhD, Gordon Cook, MD
Journal: Blood
Blood (2014) 124 (21): 3420.
https://doi.org/10.1182/blood.V124.21.3420.3420
Published: 2014
Journal Articles

Reduced Circulating Memory B-Cells Account for Humoral Immune Defects in Multiple Myeloma, Associated with Infective Risk and Poor Vaccination Responses

Jonathan Carmichael, MBBS, MRCP, Clive R Carter, Christopher Parrish, MD, Charlotte Kallmeyer, MDPhD, Sylvia Feyler, MDPhD, Philip M. Wood, FRCP, FRCPath, Gordon Cook, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3393.
https://doi.org/10.1182/blood.V124.21.3393.3393
Published: 2014
Journal Articles

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Ruth M de Tute, Anna Baginska, Christopher Parrish, MD, Shameem Mahmood, MRCP. FRCPath, Andy Rawstron, PhD, Julian D Gillmore, MD FRCP, Helen J Lachmann, MD FRCP, Philip N Hawkins, Roger G Owen, MD, Ashutosh Wechalekar, Dr
Journal: Blood
Blood (2014) 124 (21): 2073.
https://doi.org/10.1182/blood.V124.21.2073.2073
Published: 2014
Journal Articles

Interphase FISH Analysis Of Multiple Myeloma Molecular Risk At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, Christopher Parrish, MD, James D. Cavenagh, MD, John A Snowden, MD, FRCP, FRCPath, Sheila J O'Connor, Roger G Owen, MD, Julia Brown, MB, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 1884.
https://doi.org/10.1182/blood.V122.21.1884.1884
Published: 2013
Journal Articles

A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Gordon Cook, MD, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, David A Cairns, PhD, Marie Fletcher, J. D. Cavenagh, MD, MRCP, John A Snowden, MD, FRCP, FRCPath, Christopher Parrish, MD, John Ashcroft, Kwee L Yong, PhD, Jim Cavet, FRCPath, Hannah Hunter, MB, FRCPath, MRCP, Jennifer Bird, Sheila J O'Connor, Julia MB Brown, Treen Morris
Journal: Blood
Blood (2013) 122 (21): 765.
https://doi.org/10.1182/blood.V122.21.765.765
Published: 2013
Journal Articles

Lenalidomide Redresses the Effector T Cell:T reg Cell Imbalance in Patients with Multiple Myeloma.

Clive R Carter, Christopher Parrish, MD, Sylvia Feyler, MD PhD, Natuley Smalle, Gina B Scott, PhD, Charlotte Kallmeyer, MD PhD, Philip Wood, MD DPhil, Gordon Cook, MD PhD
Journal: Blood
Blood (2012) 120 (21): 2977.
https://doi.org/10.1182/blood.V120.21.2977.2977
Published: 2012